German Health Reform Law Could Shake Up Pharmaceutical Market
Executive Summary
Drug companies in the United States and Europe are warily watching a new law in Germany that could change the competitive landscape
You may also be interested in...
Pricing Experiments: Pharmas Get Creative in Germany
As Germany's insurers try out new drug reimbursement tactics, innovative pharmas have responded with novel, brand-boosting payor deals of their own. The evolution of these payor-pharma deals in Germany should inform reimbursement strategies elsewhere--including in the US where similar trends are starting to emerge.
Companies Reveal Hurdles In Providing Drugs Via Expanded Access Programs
GSK, Stealth BioTherapeutics and Blueprint Medicines discuss the difficulties getting participation of physicians, the excessive cost of expanded access, and whether physicians should report research data.